You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
明德生物(002932.SZ)上半年淨利潤2億元 同比增長397.19%
格隆匯 08-23 16:50

格隆匯8月23日丨明德生物(002932.SZ)公佈,2020年半年度,公司公司實現銷售收入3.6億元,同比增長253.98%;實現歸屬於上市公司股東的淨利潤2億元,同比增長397.19%;實現歸屬於上市公司股東的扣除非經常行損益的淨利潤為2億元,同比增長519.46%。

新冠疫情雖然嚴重擾亂了正常的社會經濟秩序,但也給IVD行業帶來了巨大的機遇和挑戰,公司抓住這一機遇,在國內取得了新冠病毒檢測試劑盒的註冊證,產品中標全國多個省市的新冠病毒檢測試劑集採;同時公司新冠病毒檢測試劑還取得了歐盟CE准入、澳大利亞TGA認證及巴西ANVISA的認證,產品遠銷海外五十多個國家。此外,公司化學發光及血氣產品入選中國醫學裝備協會推薦的新冠肺炎防治醫療設備清單,兩款儀器產品PT1000濕式血氣分析儀和CF10全自動化學發光免疫定量分析儀均榮獲2019年度“英雄杯”體外診斷年度優秀創新產品-儀器獎。

公司全資子公司武漢明志參加湖北省臨牀檢驗中心組織的新冠病毒RNA檢測能力驗證/室間質評,以PT總成績100%通過測評。同時,武漢明志積極參與武漢集中核酸檢測排查工作,努力承擔抗擊疫情的責任。

疫情期間,公司仍積極推動研發工作,2020年上半年,公司取得授權專利6件,軟件著作權6件,其中發明專利1項,實用新型專利5項;同時公司還取得產品註冊證書9件,其中一類註冊證書7件,二類註冊證書1件,三類註冊證書1件。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account